Evaluating the effects of obicetrapib and evolocumab on Lp(a) levels

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This open-label, 16-week trial aims to assess the impact of obicetrapib, both alone and in combination with evolocumab, on lipoprotein(a) [Lp(a)] levels in patients with elevated Lp(a). Participants will undergo baseline Lp(a) testing and receive daily doses of obicetrapib for the first 8 weeks, followed by a combination treatment of obicetrapib and evolocumab for the next 8 weeks. Lp(a) levels will be re-evaluated at the end of each treatment phase to determine the effectiveness of the interventions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Lp(a): \>=50 mg/dL (\>=125 nmol/L) for cohort 1 (FILLED) and Lp(a) \>= 20 mg/dL (\>= 50 nmol/L) to \<50 mg/dL (\< 125 nmol/L) for cohort 2
* LDL-C \>70 mg/dL
* TG \< 400mg/dL (\<4.52 mmol/L)

Exclusion Criteria:

* HbA1c\>=10 or FPG \>=270 mg/dL
* CV events within 3 months of screen

Where it's running

• UPenn
  Philadelphia, Pennsylvania, United States Recruiting

Study contacts

• Study coordinator: Ashley Walker
• Email: ashley.walker@newamsterdampharma.com
• Phone: 919 641 5724

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Asprosin and miRNA Profiles in Young Women with Metabolic Syndrome

  This study tests whether certain blood biomarkers, including asprosin and six microRNAs, differ between young women with metabolic syndrome and healthy peers.

  Recruiting University of Applied Sciences in Nowy Targ · Nowy Targ, Lesser Poland Voivodeship · NCT07917364

• Home-based cardiovascular health screening for people turning 50, 55, 60, 65, 70 or 75 in Uppsala

  This trial tests whether giving people a home blood pressure monitor, a dried blood spot kit, and a questionnaire can find more cardiovascular risk factors than usual care.

  Recruiting Uppsala University · Uppsala · NCT07614659

• Early LDL-C lowering with evolocumab after ACS to see if it slows plaque progression

  This trial tests whether starting evolocumab soon after a heart attack or unstable angina, in addition to standard therapy, reduces non-culprit plaque growth over a year.

  Recruiting Phase 4 West China Hospital · Xi’an, Shanxi and 1 other locations · NCT07612774

• Long-term use of inclisiran, evolocumab, and alirocumab in real-world care

  This study tests whether people with high cholesterol medications stick with their PCSK9 inhibitors and inclisiran over the long term in everyday clinical practice.

  Recruiting Novartis · Basel · NCT07543731

• Group visits to help manage high cholesterol

  This project will try group medical visits for adults with dyslipidemia to see if they improve care, lifestyle habits, and access to primary care.

  Recruiting Université de Sherbrooke · Dieppe, New Brunswick · NCT07543718

• Fixed-dose pitavastatin/ezetimibe for adults with dyslipidemia and metabolic syndrome

  This will try a fixed-dose pitavastatin/ezetimibe pill in adults with dyslipidemia and metabolic syndrome to see if it lowers LDL cholesterol and is safe over 48 weeks.

  Recruiting JW Pharmaceutical · Daejeon · NCT07523971

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.